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patients receiving coronary artery stents in a managed
care population. METHODS: Patients were selected
from the PharMetrics Integrated Outcomes Database
who underwent coronary angioplasty and stent insertion
between January 1 and June 30, 1999 and who had at
least 6 months of continuous enrollment in their health
plan following the beginning of the treatment episode.
Patients were grouped according to whether they received
outpatient anticoagulant/antiplatelet prescription drug
therapy following their stent procedure. Patients were
also stratified by history of acute myocardial infarction
(AMI) and presence of comorbid conditions (diabetes
and hypertension). Total charges associated with the
stenting treatment episode (up to 6 months following the
procedure) were assessed. RESULTS: 2,713 patients re-
ceiving anticoagulant/antiplatelet therapy and 438 un-
treated patients met all selection criteria. The two treat-
ment groups were similar in age (58.6 vs. 58.0 years
respectively, p  0.322) and in the frequency of AMI
(37.7% vs. 37.9% respectively, p  0.939) and of one or
more comorbidities (73.3% vs. 71.5% respectively, p 
0.427). Mean charges over the study period for the anti-
coagulant/antiplatelet cohort exceeded those in the un-
treated cohort by $4,748 (p  0.014). Pharmacy charges
accounted for only $297 of this excess ($660 vs. $363,
respectively). Most of the difference between treatment
groups was in the medical costs of interventional cardiol-
ogy. CONCLUSION: Among coronary stent recipients,
the mean charge for a 6-month period in patients who
also received anticoagulant/antiplatelet prescription drug
therapy was 14% higher than in the untreated cohort,
due mainly to higher medical charges. It is possible that
untreated patients were less severely ill or had a favorable
risk profile. Further investigation of these data will exam-
ine this issue.
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OBJECTIVE: To estimate the cost-effectiveness of enox-
aparin (1 mg/kg s.c. bid) vs unfractionated heparin
(UFH) (i.v. bolus and constant infusion adjusted to main-
tain a therapeutic APTT) in acute coronary syndrome
(ACS) patients from a Polish hospital perspective. The in-
tention was to facilitate the decision-making process in
selecting the most cost-effective treatment for ACS.
METHODS: Decision model was used to quantify costs
and effectiveness of alternative treatments. Published re-
sults from ESSENCE study were used to estimate the
probability for clinical end-points (death, MI, recurrent
angina) at 30 days. Probabilities of patients receiving
revascularisation procedures were obtained from the
GRACE registry (961 patients at 6 centres in Poland).
The analysis assessed only direct medical costs resulting
from the treatment of events comprising the composite
end-point, revascularisation procedures, enoxaparin and
UFH therapy, related medications. The costs were deter-
mined from actual resource consumption on a patient-
specific basis (6 months observational study) and esti-
mated using Polish data on unit costs. One- and two-way
sensitivity analysis and treshold analysis were performed.
RESULTS: At 30 days 19,8% of patients receiving enox-
aparin compared with 23,3% of patients receiving UFH
reached one event of the composite end-point (p  0,02).
The average costs (in PLN, 1 USD  4 PLN) were 1085
per patient receiving enoxaparin compared with 1097 per
patient receiving UFH. Therefore for every 29 patients
treated, enoxaparin therapy would not only avoid one
event of the composite end-point, it would also save 348
PLN. The threshold analysis revealed, that enoxaparin
would lose the dominance, when cost of enoxaparin ther-
apy would increase by 30%, cost of UFH—decrease by
47%, probability end-point in enoxaparin arm increase
to 0.22 or in UFH arm decrease to 0.2. CONCLUSION:
Since enoxaparin resulted in a better effect at a lower
cost, this antithrombotic strategy was considered to be
dominant for Polish patients with ACS.
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OBJECTIVE: The objective of this study was to examine
the role of quality of life (QOL) and patient preference as
predictors for resource utilization among patients with
heart failure (HF). METHODS: QOL, patient preference,
resource utilization, and survival are being assessed in 94
patients with HF managed in an urban HF specialty
clinic. QOL is measured using a disease-specific question-
naire, the Kansas City Cardiomyopathy Questionnaire
(KCCQ) and a generic questionnaire, the Short Form 12
(SF-12), at baseline, 3 months, and 6 months. Patient
preference is measured using standard gamble technique
at baseline. Resource use including hospitalization, ER
visits, procedures, and outpatient visits are captured by
patient interview and verified by clinic and hospital
records. Health care costs are derived from clinic cost
data, University Health System Consortium database,
and literature. RESULTS: To date, 81 patients have com-
pleted 3 months follow-up (mean age 49.9  14.0 years;
69% African American; 53% male; NYHA class I  15,
